Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.49 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | IGF2R | P11717 | 1/20 | 0.44 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18880345 | 1.00 | GAA (0.50) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL18880342 | 1.00 | GAA (0.50) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL20873292 | 1.00 | GAA (0.50) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL2452644 | 1.00 | GAA (0.50) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL12302591 | 1.00 | GAA (0.50) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL8184630 | 0.90 | LGALS3 (0.64) | LGALS8LGALS3LGALS4IGF2RCD209 | |
| SCHEMBL8184633 | 0.90 | LGALS3 (0.64) | LGALS8LGALS3LGALS4IGF2RCD209 | |
| SCHEMBL9220642 | 0.85 | GAA (0.59) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL10622349 | 0.85 | GAA (0.59) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL8654354 | 0.83 | IGF2R (0.44) | GAALGALS8LGALS3LGALS4IGF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258043-A1 | Linkable Lewis X Analogs | BRACCO SUISSE S.A. (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20110229409-A1 | LINKABLE LEWIS X ANALOGS | BRACCO INTERNATIONAL B.V. (NL) | 2011-09-22 | — | — | US | disclosed |
| US-20080300220-A1 | Linkable Lewis X Analogs | BRACCO INTERNATIONAL B.V. (NL) | 2008-12-04 | — | — | US | disclosed |
| US-7422733-B2 | Linkable sialyl Lewis X analogs | BRACCO INTERNATIONAL B.V. (NL) | 2008-09-09 | — | — | US | disclosed |
| US-20040097403-A1 | Linkable sialyl lewis x analogs | BRACCO SUISSE SA (CH) | 2004-05-20 | — | — | US | disclosed |
| EP-1337539-A2 | LINKABLE SIALYL LEWIS X ANALOGS | BRACCO INTERNATIONAL B.V. (NL) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002062810-A2 | LINKABLE SIALYL LEWIS X ANALOGS | BRACCO INTERNATIONAL B.V. (NL) | 2002-08-15 | — | — | WO | disclosed |
| US-4871837-A | DEPROTECTING SILYL-PROTECTED CARBOHYDRATES, AMINO ACIDS, PEPTIDES; LEWIS ACID HYDROLYSIS | SYMBICOM AKTIEBOLAG (SE) | 1989-10-03 | — | — | US | disclosed |
| EP-0239194-A2 | Methods for preparing hydroxy compounds and intermediates | SYMBICOM AB (SE) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300220-A1 | Linkable Lewis X Analogs | SSB, SELPLG, SELL | GAA 1200/4885LGALS8 318/4885LGALS3 152/4885 |
| US-20120258043-A1 | Linkable Lewis X Analogs | SSB, SELPLG, SELL | GAA 1200/4885LGALS8 318/4885LGALS3 152/4885 |
| US-20040097403-A1 | Linkable sialyl lewis x analogs | SSB, SELPLG, SELL | GAA 990/4885LGALS8 214/4885LGALS3 93/4885 |
| US-20110229409-A1 | LINKABLE LEWIS X ANALOGS | SELPLG, SELL, SELE | GAA 663/4885LGALS8 147/4885LGALS3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.